Skip to content
2000
Volume 25, Issue 2
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

There is no abstract available.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096343056240828190900
2024-09-07
2025-02-19
Loading full text...

Full text loading...

/deliver/fulltext/ccdt/25/2/CCDT-25-2-02.html?itemId=/content/journals/ccdt/10.2174/0115680096343056240828190900&mimeType=html&fmt=ahah

References

  1. Abdus SubhanM. TorchilinV.P. Advances with antibody-drug conjugates in breast cancer treatment.Eur. J. Pharm. Biopharm.202116924125510.1016/j.ejpb.2021.10.016 34748933
    [Google Scholar]
  2. RitchieM. TchistiakovaL. ScottN. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates.MAbs201351132110.4161/mabs.22854 23221464
    [Google Scholar]
  3. MahalingaiahP.K. CiurlionisR. DurbinK.R. YeagerR.L. PhilipB.K. BawaB. MantenaS.R. EnrightB.P. LiguoriM.J. Van VleetT.R. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.Pharmacol. Ther.201920011012510.1016/j.pharmthera.2019.04.008 31028836
    [Google Scholar]
  4. GiuglianoF. CortiC. TarantinoP. MicheliniF. CuriglianoG. Bystander effect of antibody–drug conjugates: Fact or fiction?Curr. Oncol. Rep.202224780981710.1007/s11912‑022‑01266‑4 35305211
    [Google Scholar]
  5. MaqboolM. BekeleF. FekaduG. Treatment strategies against triple-negative breast cancer: An updated review.Breast Cancer (Dove Med. Press)202214152410.2147/BCTT.S348060 35046722
    [Google Scholar]
  6. SahinT.K. RizzoA. AksoyS. GuvenD.C. Prognostic significance of the royal marsden hospital (rmh) score in patients with cancer: A systematic review and meta-analysis.Cancers (Basel)20241610183510.3390/cancers16101835 38791914
    [Google Scholar]
  7. DragoJ.Z. ModiS. ChandarlapatyS. Unlocking the potential of antibody–drug conjugates for cancer therapy.Nat. Rev. Clin. Oncol.202118632734410.1038/s41571‑021‑00470‑8 33558752
    [Google Scholar]
  8. HussainM.S. MajamiA.A. AliH. GuptaG. AlmalkiW.H. AlzareaS.I. KazmiI. SyedR.U. KhalifaN.E. Bin BreakM.K. KhanR. AltwaijryN. SharmaR. The complex role of MEG3: An emerging long non-coding RNA in breast cancer.Pathol. Res. Pract.202325115485010.1016/j.prp.2023.154850 37839358
    [Google Scholar]
  9. RizzoA. MollicaV. TateoV. TassinariE. MarchettiA. RoselliniM. De LucaR. SantoniM. MassariF. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: The MOUSEION-05 study.Cancer Immunol. Immunother.20237261381139410.1007/s00262‑023‑03366‑x 36695827
    [Google Scholar]
  10. RizzoA. CusmaiA. AcquafreddaS. RinaldiL. PalmiottiG. Ladiratuzumab vedotin for metastatic triple negative cancer: Preliminary results, key challenges, and clinical potential.Expert Opin. Investig. Drugs202231649549810.1080/13543784.2022.2042252 35171746
    [Google Scholar]
  11. GuvenD.C. ErulE. KaygusuzY. AkagunduzB. KilickapS. De LucaR. RizzoA. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data.Support. Care Cancer2023311162410.1007/s00520‑023‑08083‑w 37819422
    [Google Scholar]
  12. AdamsE. WildiersH. NevenP. PunieK. Sacituzumab govitecan and trastuzumab deruxtecan: Two new antibody–drug conjugates in the breast cancer treatment landscape.ESMO Open20216410020410.1016/j.esmoop.2021.100204 34225076
    [Google Scholar]
  13. HartleyJ.A. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.Expert Opin. Biol. Ther.202121793194310.1080/14712598.2020.1776255 32543981
    [Google Scholar]
  14. NajjarM.K. ManoreS.G. ReguaA.T. LoH.W. Antibody-drug conjugates for the treatment of HER2-positive breast cancer.Genes (Basel)20221311206510.3390/genes13112065 36360302
    [Google Scholar]
  15. KalinskyK. SpringL. YamC. BhaveM.A. NtallaI. LaiC. SjeklocaN. StwalleyB. StokesM. TaylorA. NandaR. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.Breast Cancer Res. Treat.202410.1007/s10549‑024‑07412‑9 38904892
    [Google Scholar]
  16. GoelS. TanA.R. RugoH.S. AftimosP. AndrićZ. BeelenA. ZhangJ. YiJ.S. MalikR. O’ShaughnessyJ. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: Phase III PRESERVE 2.Future Oncol.202218333701371110.2217/fon‑2022‑0773 36135712
    [Google Scholar]
  17. FurlanettoJ. MarméF. LoiblS. Sacituzumab govitecan: Past, present and future of a new antibody-drug conjugate and future horizon.Future Oncol.202218283199321510.2217/fon‑2022‑0407 36069628
    [Google Scholar]
  18. SpringL.M. TolaneyS.M. FellG. BossuytV. AbelmanR.O. WuB. MaheswaranS. TrippaL. ComanderA. MulveyT. McLaughlinS. RyanP. RyanL. AbrahamE. RosenstockA. Garrido-CastroA.C. LynceF. MoyB. IsakoffS.J. TungN. MittendorfE.A. EllisenL.W. BardiaA. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: Results from the NeoSTAR trial.Ann. Oncol.202435329330110.1016/j.annonc.2023.11.018 38092228
    [Google Scholar]
  19. MarméF. HanuschC. FurlanettoJ. DenkertC. LinkT. UntchM. BlohmerJ-U. JackischC. ReinischM. RhiemK.E. SchneeweissA. SolbachC. SchöllhornL. FaschingP.A. ReyJ. LoiblS. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.Ann. Oncol.202132S443S44410.1016/j.annonc.2021.08.480
    [Google Scholar]
  20. BardiaA. PunieK. BarriosC.H. SchneeweissA. ZhaiX. VaksmanN. LaiC. TolaneyS.M. 275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC).Ann. Oncol.202233S663S66410.1016/j.annonc.2022.07.1859
    [Google Scholar]
  21. BardiaA. CoatesJ.T. SpringL. SunS. JuricD. ThimmiahN. NiemierkoA. RyanP. PartridgeA. artridge, J. Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation.Cancer Res.2022822638
    [Google Scholar]
  22. ModiS. JacotW. YamashitaT. SohnJ. VidalM. TokunagaE. TsurutaniJ. UenoN.T. PratA. ChaeY.S. LeeK.S. NiikuraN. ParkY.H. XuB. WangX. Gil-GilM. LiW. PiergaJ.Y. Im, S.A.; Moore, H.C.F.; Rugo, H.S.; Yerushalmi, R.; Zagouri, F.; Gombos, A.; Kim, S.B.; Liu, Q.; Luo, T.; Saura, C.; Schmid, P.; Sun, T.; Gambhire, D.; Yung, L.; Wang, Y.; Singh, J.; Vitazka, P.; Meinhardt, G.; Harbeck, N.; Cameron, D.A. Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer.N. Engl. J. Med.2022387192010.1056/NEJMoa2203690 35665782
    [Google Scholar]
  23. TakegawaN. NonagaseY. YonesakaK. SakaiK. MaenishiO. OgitaniY. TamuraT. NishioK. NakagawaK. TsurutaniJ. DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance.Int. J. Cancer201714181682168910.1002/ijc.30870 28677116
    [Google Scholar]
  24. RizzoA. RinaldiL. MassafraR. CusmaiA. GuvenD.C. ForgiaD. LatorreA. GiottaF. Sacituzumab govitecan vs. chemotherapy for] metastatic breast cancer: A meta-analysis on safety outcomes.Future Oncol.20241810.1080/14796694.2024.2354162:1‑8 38864297
    [Google Scholar]
  25. KubliS.P. BergerT. AraujoD.V. SiuL.L. MakT.W. Beyond immune checkpoint blockade: Emerging immunological strategies.Nat. Rev. Drug Discov.2021201289991910.1038/s41573‑021‑00155‑y 33686237
    [Google Scholar]
  26. GunturuK.S. PhamT.T. ShambhuS. FischM.J. BarronJ.J. DebonoD. Immune checkpoint inhibitors: Immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients.Support. Care Cancer20223054019402610.1007/s00520‑022‑06826‑9 35064328
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096343056240828190900
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test